Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 156

1.

The type III TGF-beta receptor suppresses breast cancer progression through GIPC-mediated inhibition of TGF-beta signaling.

Lee JD, Hempel N, Lee NY, Blobe GC.

Carcinogenesis. 2010 Feb;31(2):175-83. doi: 10.1093/carcin/bgp271. Epub 2009 Dec 2.

2.

The type III TGF-beta receptor suppresses breast cancer progression.

Dong M, How T, Kirkbride KC, Gordon KJ, Lee JD, Hempel N, Kelly P, Moeller BJ, Marks JR, Blobe GC.

J Clin Invest. 2007 Jan;117(1):206-17. Epub 2006 Dec 7.

3.
4.

Ectodomain shedding of TβRIII is required for TβRIII-mediated suppression of TGF-β signaling and breast cancer migration and invasion.

Elderbroom JL, Huang JJ, Gatza CE, Chen J, How T, Starr M, Nixon AB, Blobe GC.

Mol Biol Cell. 2014 Aug 15;25(16):2320-32. doi: 10.1091/mbc.E13-09-0524. Epub 2014 Jun 25.

5.

Roles for the type III TGF-beta receptor in human cancer.

Gatza CE, Oh SY, Blobe GC.

Cell Signal. 2010 Aug;22(8):1163-74. doi: 10.1016/j.cellsig.2010.01.016. Epub 2010 Feb 12. Review.

6.

TbetaRIII suppresses non-small cell lung cancer invasiveness and tumorigenicity.

Finger EC, Turley RS, Dong M, How T, Fields TA, Blobe GC.

Carcinogenesis. 2008 Mar;29(3):528-35. doi: 10.1093/carcin/bgm289. Epub 2008 Jan 3.

PMID:
18174241
7.

Expression of the type III TGF-beta receptor is negatively regulated by TGF-beta.

Hempel N, How T, Cooper SJ, Green TR, Dong M, Copland JA, Wood CG, Blobe GC.

Carcinogenesis. 2008 May;29(5):905-12. doi: 10.1093/carcin/bgn049. Epub 2008 Feb 24.

8.

Type III TGF-β receptor enhances colon cancer cell migration and anchorage-independent growth.

Gatza CE, Holtzhausen A, Kirkbride KC, Morton A, Gatza ML, Datto MB, Blobe GC.

Neoplasia. 2011 Aug;13(8):758-70.

9.

The type III TGF-beta receptor regulates epithelial and cancer cell migration through beta-arrestin2-mediated activation of Cdc42.

Mythreye K, Blobe GC.

Proc Natl Acad Sci U S A. 2009 May 19;106(20):8221-6. doi: 10.1073/pnas.0812879106. Epub 2009 May 1.

10.

The type III transforming growth factor-beta receptor negatively regulates nuclear factor kappa B signaling through its interaction with beta-arrestin2.

You HJ, How T, Blobe GC.

Carcinogenesis. 2009 Aug;30(8):1281-7. doi: 10.1093/carcin/bgp071. Epub 2009 Mar 26.

11.

The type III TGF-beta receptor signals through both Smad3 and the p38 MAP kinase pathways to contribute to inhibition of cell proliferation.

You HJ, Bruinsma MW, How T, Ostrander JH, Blobe GC.

Carcinogenesis. 2007 Dec;28(12):2491-500. Epub 2007 Sep 3.

PMID:
17768179
12.

Transforming growth factor beta receptor type III is a tumor promoter in mesenchymal-stem like triple negative breast cancer.

Jovanović B, Beeler JS, Pickup MW, Chytil A, Gorska AE, Ashby WJ, Lehmann BD, Zijlstra A, Pietenpol JA, Moses HL.

Breast Cancer Res. 2014 Jul 1;16(4):R69. doi: 10.1186/bcr3684.

13.

Hyaluronan promotes signaling interaction between CD44 and the transforming growth factor beta receptor I in metastatic breast tumor cells.

Bourguignon LY, Singleton PA, Zhu H, Zhou B.

J Biol Chem. 2002 Oct 18;277(42):39703-12. Epub 2002 Jul 26.

14.

The balance of cell surface and soluble type III TGF-β receptor regulates BMP signaling in normal and cancerous mammary epithelial cells.

Gatza CE, Elderbroom JL, Oh SY, Starr MD, Nixon AB, Blobe GC.

Neoplasia. 2014 Jun;16(6):489-500. doi: 10.1016/j.neo.2014.05.008.

15.

Decreased expression of the type III TGF-β receptor enhances metastasis and invasion in hepatocellullar carcinoma progression.

Zhang S, Sun WY, Wu JJ, Gu YJ, Wei W.

Oncol Rep. 2016 Apr;35(4):2373-81. doi: 10.3892/or.2016.4615. Epub 2016 Feb 8.

PMID:
26882862
16.

Loss of type III transforming growth factor-beta receptor expression is due to methylation silencing of the transcription factor GATA3 in renal cell carcinoma.

Cooper SJ, Zou H, Legrand SN, Marlow LA, von Roemeling CA, Radisky DC, Wu KJ, Hempel N, Margulis V, Tun HW, Blobe GC, Wood CG, Copland JA.

Oncogene. 2010 May 20;29(20):2905-15. doi: 10.1038/onc.2010.64. Epub 2010 Mar 8.

17.

Diffuse-type gastric carcinoma: progression, angiogenesis, and transforming growth factor beta signaling.

Komuro A, Yashiro M, Iwata C, Morishita Y, Johansson E, Matsumoto Y, Watanabe A, Aburatani H, Miyoshi H, Kiyono K, Shirai YT, Suzuki HI, Hirakawa K, Kano MR, Miyazono K.

J Natl Cancer Inst. 2009 Apr 15;101(8):592-604. doi: 10.1093/jnci/djp058. Epub 2009 Apr 7.

18.

The type III transforming growth factor-β receptor inhibits proliferation, migration, and adhesion in human myeloma cells.

Lambert KE, Huang H, Mythreye K, Blobe GC.

Mol Biol Cell. 2011 May;22(9):1463-72. doi: 10.1091/mbc.E10-11-0877. Epub 2011 Mar 16.

19.

Silencing of transforming growth factor-beta1 in situ by RNA interference for breast cancer: implications for proliferation and migration in vitro and metastasis in vivo.

Moore LD, Isayeva T, Siegal GP, Ponnazhagan S.

Clin Cancer Res. 2008 Aug 1;14(15):4961-70. doi: 10.1158/1078-0432.CCR-07-4604.

20.

Ki26894, a novel transforming growth factor-beta type I receptor kinase inhibitor, inhibits in vitro invasion and in vivo bone metastasis of a human breast cancer cell line.

Ehata S, Hanyu A, Fujime M, Katsuno Y, Fukunaga E, Goto K, Ishikawa Y, Nomura K, Yokoo H, Shimizu T, Ogata E, Miyazono K, Shimizu K, Imamura T.

Cancer Sci. 2007 Jan;98(1):127-33.

Supplemental Content

Support Center